Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–50
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Healthy male 18 to 50 years old inclusive with suitable veins for cannulation or repeated venipuncture
Have a body mass index (BMI) between 19 and 30 kg/m2 inclusive and weigh at least 50 kg
Male subjects should be willing to use a double barrier method of contraception (condom with spermicide) from the first dose of investigational product until 3 months after the last dose of investigational product
Be able to understand and comply with the requirements of the study as judged by the investigator
You may not be if
History of any clinically significant medical, neurologic or psychiatric disease or disorder which, in the opinion of the Investigator and Sponsor may either put the subject at risk because of participation in the study, or influence the results of the subject's ability to participate in the study
History or presence of gastrointestinal (including irritable bowel disease), hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of study drug. Subjects with a history of surgery on the gastrointestinal tract (not including appendectomy or cholecystectomy) should also be excluded
History of seizure activity, including febrile seizures
Prolonged QTcF \>450 ms or shortened QTcF \<340 ms, or family history of Long QT Syndrome
Use of concomitant medications that prolong QT/QTc interval
Clareo Health | Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
